CA
BIOA

Clearstead Advisors’s BioAge Labs BIOA Stock Holding History

Clearstead Advisors’s Portfolio BIOA Stock Details BIOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-18
Closed -$106 – 3309
2025
Q3 		$106 Hold
18
– – ﹤0.01% 2927
2025
Q2 		$75 Buy
+18
New +$73 ﹤0.01% 2643

Other funds holding BIOA

ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $308M AUM 120.89% 1-Year Est. Return

Clearstead Advisors's BIOA Position: Q4 2025 in Review

Clearstead Advisors sold out of BioAge Labs (BIOA) in Q4 2025, closing a stake of 18 shares — an estimated $106 sold.

Clearstead Advisors first reported a position in BIOA in Q2 2025 and held it in 2 quarters. The position peaked at $106 in Q3 2025. 114 funds tracked by Wall St. Rank hold BIOA as of Q4 2025.

  • Clearstead Advisors reported no remaining BioAge Labs position as of Q4 2025 after selling out during the quarter.
  • Clearstead Advisors sold 18 BioAge Labs shares in Q4 2025, an estimated $106.
  • Clearstead Advisors first reported a position in BioAge Labs in Q2 2025 and held it in 2 quarters.
  • Clearstead Advisors's BioAge Labs position peaked at $106 in Q3 2025.
  • 114 funds tracked by Wall St. Rank held BioAge Labs as of Q4 2025.

Based on Clearstead Advisors's 13F filing for Q4 2025, filed 9 Feb 2026.